After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

American Express, Cencora and Tempur Sealy International have been highlighted in this Screen of The Week article.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency ...

The Trump administration’s moves to trim government spending pose a short-term “understated risk” for companies all across ...

Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. (COR) is a leading pharmaceutical services company dedicated to ...

Shares of Cencora Inc. COR shed 1.28% to $243.59 Wednesday, on what proved to be an all-around grim trading session for the ...

Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...

Cencora, Inc. (NYSE: COR) has announced a repurchase of its common stock from Walgreens Boots Alliance Holdings LLC, ...